Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (68 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.W | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > I Thought The 100 people where picked
View:
Post by gonefishing2022 on Jan 08, 2024 11:27am

I Thought The 100 people where picked

So I thought the 100 people were picked,he says by 2026.it takes 1.5 years 450 day mark for study unless I'm wrong. SO why will this go up anytime real soon. If they get Break Through can this become mainstream help for people.
Comment by tdon1229 on Jan 08, 2024 12:29pm
Gonefishing2022, If they get BTD, then they'll be looking for the AA to follow.  AA gives them the ability to begin charging patients for the costs of the treatment, including the remaining trial patients. That brings in money, but also makes the treatment more attractive to potential partners, whether for licensing, joint venture, or buy out options.  More desirability = higher ...more  
Comment by gonefishing2022 on Jan 08, 2024 12:50pm
THANKS for your info I thought they had 100 people picked already and Treatment was already done. I have a lot of chips in This for last 3 years and was hoping by in the next couple of months they would get BTD and hopefully the stock goes over. 50 cent6.Thanks again 
Comment by Eoganacht on Jan 08, 2024 1:33pm
Great post tdon1229. AA might also make the treatment more attractive to patients and their doctors and might speed up enrollment. As Roger pointed out, CIS is a rare high-grade form of NMIBC (10%) and we are only treating the ones that are BCG-unresponsive. And there is competition for these patients from other, more high-profile clinical trials. Theralase has only 11 study sites to work with ...more  
Comment by 99942Apophis on Jan 09, 2024 11:08am
tdon1229 wrote  If they get BTD, then they'll be looking for the AA to follow.  AA gives them the ability to begin charging patients for the costs of the treatment, including the remaining trial patients. That brings in money, but also makes the treatment more attractive to potential partners, whether for licensing, joint venture, or buy out options.  More desirability = higher ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 68 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250